Paroxetine
|
|
|
- CAS-Nr.
- 61869-08-7
- Englisch Name:
- Paroxetine
- Synonyma:
- PAXIL;PAROXETIN HCL;AROPAX;FG 7051;BRL 29060;AROPAX 20;Paloxitene;PAROXETINE;PARORETINE HCL;Paroxetine 99%
- CBNumber:
- CB5178021
- Summenformel:
- C19H20FNO3
- Molgewicht:
- 329.37
- MOL-Datei:
- 61869-08-7.mol
|
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Paroxetine Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Paroxetine is a new highly selective serotonin reuptake inhibitor, mechanistically
similar to fluoxetine, fluvoxamine and sertraline, introduced for the treatment of all
types of depressive illnesses including depression associated with anxiety. It is
reportedly non-sedating and non-stimulatory and compared to fluoxetine has a shorter
duration of action (half-life of 24 hours versus 2 to 3 days). Paroxetine is also being
investigated as a treatment for obesity, alcoholism and obsessive-compulsive disorders.
Chemische Eigenschaften
White Solid
Verwenden
A istopically labelled selective serotonin reuptake inhibitor. Used as an antidepressant
Biologische Funktion
Paroxetine (Paxil) has an elimination half-life of 21
hours and is also highly bound to plasma proteins, so it
requires special attention when administered with drugs
such as warfarin. Paroxetine is a potent inhibitor of the
cytochrome P450 2D6 isoenzyme and can raise the
plasma levels of drugs metabolized via this route. Of
particular concern are drugs with a narrow therapeutic
index, such as TCAs and the type 1C antiarrhythmics
flecainide, propafenone, and encainide. Additionally,
paroxetine itself is metabolized by this enzyme and inhibits
its own metabolism, leading to nonlinear kinetics.
Weight gain is higher with paroxetine than with the
other SSRIs, and it tends to be more sedating, presumably
because of its potential anticholinergic effects.
Additionally, patients have had difficulty with abrupt
discontinuation with this agent, reporting a flulike syndrome;
this symptom can be avoided by tapering the
medication.
Allgemeine Beschreibung
In the structure of paroxetine (Paxil), an amino group, protonatedin vivo could H-bond with the–CH
2–O– unshared electrons.A β-arylamine–like structure with an extra aryl groupresults. The compound is a very highly selective SERT. Asexpected, it is an effective antidepressant and anxiolytic.
Clinical Use
In vitro binding studies suggest that paroxetine is a more
selective and potent inhibitor of 5-HT reuptake than fluoxetine. The drug essentially has no effect on NE or
dopamine reuptake, nor does it show affinity for other neuroreceptors. Its onset of action is 1 to 4 weeks.
Paroxetine Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Paroxetine Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 240)Lieferanten
61869-08-7()Verwandte Suche:
- 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-,(3s,4r)-piperidin
- 3α-(1,3-Benzodioxole-5-yloxymethyl)-4β-(4-fluorophenyl)piperidine
- 3α-[(1,3-Benzodioxol-5-yl)oxymethyl]-4β-(4-fluorophenyl)piperidine
- (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)Methyl]-4-(4-fluorophenyl)piperidine
- Paroxetine HCl anhydrous API
- (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
- Paloxitene
- Piperidine,3-[(1,3-benzodioxol-5-yloxy)Methyl]-4-(4-fluorophenyl)-, (3S,4R)-
- 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-piperidin(3s-trans)
- BRL 29060
- AROPAX
- AROPAX 20
- FG 7051
- PAROXETIENE BASE
- PAROXETINE
- (-)-TRANS-4R-(4'-FLUOROPHENYL)-3S-[(3',4'-METHYLENEDIOXY-PHENOXY) METHYL]PIPERIDINE
- rac trans-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine Hydrochloride
- (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine
- Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)- (9CI)
- Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)-
- (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
- (-)-trans-4R-(4'-Fluorophenyl)-3S-((3',4'-methylenedioxyphenoxy)methyl)piperidine
- PARORETINE HCL
- ParoxetineHclBase
- (3S,4R)-3-[(1,3-BENZODIOXOL-5-YLOXY)METHYL]-4-(4-FFLUOROPHENYL)PIPERIDINE
- (-)-trans-4-(4-Fluorophenyl)-3-hydroxy methyl-N-me
- (3R)-3α-[3,4-(Methylenebisoxy)phenoxymethyl]-4β-(4-fluorophenyl)piperidine
- Paroxetine-002-SR
- Paroxetine-002-3S4R
- 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine hydrate hydrochloride
- Paroxetine hydrochloride (anhydrous) CRS
- Paroxetine for system suitability CRS
- trans-(-)-3-[(1，3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
- Paroxetine USP/EP/BP
- Paroxetine 99%
- PAXIL
- PAROXETIN HCL
- Paroxetine EP Standard
- (-)-Paroxetine
- 61869-08-7
- C19H17D4ClFNO3
- C19H20FNO3
- Inhibitors
- Intermediates & Fine Chemicals
- Isotope Labeled Compounds
- Pharmaceuticals
- API's
- Paroxetine
- Fluorobenzene
- APIs
- 61869-08-7
